FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316525940> ?p ?o ?g. }

• W2316525940 endingPage "379" @default.
• W2316525940 startingPage "375" @default.
• W2316525940 abstract "Background: The standard for early posttraumatic brain injury (TBI) seizure prophylaxis is phenytoin. Despite its effectiveness, some argue for the use of newer antiepileptics (e.g., levetiracetam) because phenytoin requires close monitoring to maintain its therapeutic window and is associated with rare cutaneous hypersensitivity reactions. The purpose of this study was to evaluate whether phenytoin or levetiracetam would be more cost-effective in preventing early post-TBI seizures and reducing their negative impact on TBI outcomes. Methods: Cost-effectiveness analysis with the following base case assumptions: (1) phenytoin patients receive 1.0 g fosphenytoin load + 3 days of 100 mg three times a day (TID), have level drawn on day 3, “therapeutic” patients receive 100 mg TID on days 4 to 7, and “subtherapeutic” patients receive 200 mg TID on days 4 to 7; (2) levetiracetam patients receive 500 mg load + 7 days of 500 mg two times a day. Glasgow Outcome Scale (GOS) scores 4 to 5 represent good outcome, and GOS scores 2 to 3 represent poor outcome. Patients who develop early seizures: 40% good outcome, 50% poor outcome, and 10% death. Those who do not develop seizures: 75% good outcome, 20% poor outcome, and 5% death. Quality of life outcomes by GOS: good = 0.7, poor = 0.3, and death = 0.0. Severe adverse events and those impacting costs are rare for each agent. Assumptions were obtained through hospital query and exhaustive literature review. Results: The cost of a 7-day course of fosphenytoin, phenytoin, and free phenytoin level was $37.50, whereas the cost of a 7-day course of levetiracetam was $480.00. Literature review noted phenytoin to be as effective as levetiracetam in preventing early post-TBI seizures (and more effective in subclinical seizures). Quality-adjusted life years (QALY) were 23.6 for phenytoin and 23.2 for levetiracetam. As a result, the cost/effectiveness ratios were $1.58/QALY for phenytoin and $20.72/QALY for levetiracetam. All sensitivity analyses favored phenytoin unless levetiracetam prevented 100% of seizures and cost <$400 for 7-day course. Conclusions: Phenytoin is more cost-effective than levetiracetam at all reasonable prices and at all clinically plausible reductions in post-TBI seizure potential." @default.
• W2316525940 created "2016-06-24" @default.
• W2316525940 creator A5022085835 @default.
• W2316525940 creator A5042251160 @default.
• W2316525940 creator A5071697044 @default.
• W2316525940 creator A5090675988 @default.
• W2316525940 date "2011-08-01" @default.
• W2316525940 modified "2023-09-25" @default.
• W2316525940 title "Cost-Utility Analysis of Levetiracetam and Phenytoin for Posttraumatic Seizure Prophylaxis" @default.
• W2316525940 cites W1557124033 @default.
• W2316525940 cites W1967996835 @default.
• W2316525940 cites W1975711535 @default.
• W2316525940 cites W1978046719 @default.
• W2316525940 cites W1983410753 @default.
• W2316525940 cites W1989887789 @default.
• W2316525940 cites W1999591072 @default.
• W2316525940 cites W2001124492 @default.
• W2316525940 cites W2019957633 @default.
• W2316525940 cites W2028344559 @default.
• W2316525940 cites W2036295400 @default.
• W2316525940 cites W2038026687 @default.
• W2316525940 cites W2038898672 @default.
• W2316525940 cites W2039369548 @default.
• W2316525940 cites W2050086797 @default.
• W2316525940 cites W2051431048 @default.
• W2316525940 cites W2077469857 @default.
• W2316525940 cites W2081073379 @default.
• W2316525940 cites W2082863795 @default.
• W2316525940 cites W2095415351 @default.
• W2316525940 cites W2108927105 @default.
• W2316525940 cites W2113615687 @default.
• W2316525940 cites W2114412610 @default.
• W2316525940 cites W2115242371 @default.
• W2316525940 cites W2118367858 @default.
• W2316525940 cites W2148885221 @default.
• W2316525940 cites W2150857727 @default.
• W2316525940 cites W2167736247 @default.
• W2316525940 cites W2325851205 @default.
• W2316525940 cites W2336409300 @default.
• W2316525940 cites W54018717 @default.
• W2316525940 doi "https://doi.org/10.1097/ta.0b013e318224d307" @default.
• W2316525940 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21825941" @default.
• W2316525940 hasPublicationYear "2011" @default.
• W2316525940 type Work @default.
• W2316525940 sameAs 2316525940 @default.
• W2316525940 citedByCount "37" @default.
• W2316525940 countsByYear W23165259402012 @default.
• W2316525940 countsByYear W23165259402013 @default.
• W2316525940 countsByYear W23165259402014 @default.
• W2316525940 countsByYear W23165259402015 @default.
• W2316525940 countsByYear W23165259402016 @default.
• W2316525940 countsByYear W23165259402017 @default.
• W2316525940 countsByYear W23165259402018 @default.
• W2316525940 countsByYear W23165259402019 @default.
• W2316525940 countsByYear W23165259402021 @default.
• W2316525940 countsByYear W23165259402022 @default.
• W2316525940 crossrefType "journal-article" @default.
• W2316525940 hasAuthorship W2316525940A5022085835 @default.
• W2316525940 hasAuthorship W2316525940A5042251160 @default.
• W2316525940 hasAuthorship W2316525940A5071697044 @default.
• W2316525940 hasAuthorship W2316525940A5090675988 @default.
• W2316525940 hasConcept C118552586 @default.
• W2316525940 hasConcept C126322002 @default.
• W2316525940 hasConcept C17624336 @default.
• W2316525940 hasConcept C197934379 @default.
• W2316525940 hasConcept C2775858608 @default.
• W2316525940 hasConcept C2777332695 @default.
• W2316525940 hasConcept C2777796830 @default.
• W2316525940 hasConcept C2778186239 @default.
• W2316525940 hasConcept C2778337148 @default.
• W2316525940 hasConcept C2781017439 @default.
• W2316525940 hasConcept C42219234 @default.
• W2316525940 hasConcept C71924100 @default.
• W2316525940 hasConceptScore W2316525940C118552586 @default.
• W2316525940 hasConceptScore W2316525940C126322002 @default.
• W2316525940 hasConceptScore W2316525940C17624336 @default.
• W2316525940 hasConceptScore W2316525940C197934379 @default.
• W2316525940 hasConceptScore W2316525940C2775858608 @default.
• W2316525940 hasConceptScore W2316525940C2777332695 @default.
• W2316525940 hasConceptScore W2316525940C2777796830 @default.
• W2316525940 hasConceptScore W2316525940C2778186239 @default.
• W2316525940 hasConceptScore W2316525940C2778337148 @default.
• W2316525940 hasConceptScore W2316525940C2781017439 @default.
• W2316525940 hasConceptScore W2316525940C42219234 @default.
• W2316525940 hasConceptScore W2316525940C71924100 @default.
• W2316525940 hasIssue "2" @default.
• W2316525940 hasLocation W23165259401 @default.
• W2316525940 hasLocation W23165259402 @default.
• W2316525940 hasOpenAccess W2316525940 @default.
• W2316525940 hasPrimaryLocation W23165259401 @default.
• W2316525940 hasRelatedWork W1985056740 @default.
• W2316525940 hasRelatedWork W1986230450 @default.
• W2316525940 hasRelatedWork W1989493783 @default.
• W2316525940 hasRelatedWork W1996258496 @default.
• W2316525940 hasRelatedWork W2039203321 @default.
• W2316525940 hasRelatedWork W2150101439 @default.
• W2316525940 hasRelatedWork W2752231409 @default.
• W2316525940 hasRelatedWork W2955536017 @default.

• next